계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
TG Therapeutics
About
TG Therapeutics, a biopharmaceutical company, develops agents for the treatment of hematologic malignancies and autoimmune disorders.
- 51 - 100
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $70M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 1993
- Number Of Employee
- 51 - 100
- Operating Status
- Active
TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 4, 2022 | Post-IPO Debt | $70M | 1 |
Hercules Capital
|
— | Detail |
| Feb 28, 2019 | Post-IPO Debt | $60M | 1 |
Hercules Capital
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
